Transcribed
Gene Therapy for Heart Failure: What Comes Next? | Patrick Most
1:14:28
Professor Patrick Most traces a 25-year journey from discovering a molecule that boosts heart contractility during his doctoral thesis, through two biotech startups, to Aavigen's mission to deliver the first cardiac gene therapy by intravenous injection by end of 2027.
Patrick Most is Professor of Molecular and Translational Cardiology at Heidelberg University and founder of Aavigen, which…